CompletedNot Applicable

Caffeine, CYPA12 and Resistance Exercise

Spain60 participantsStarted 2024-04-01

Plain-language summary

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to be elucidated how CYP1A2 polymorphism influences the acute effects of caffeine on this type of exercise. Objectives: The present study aims to analyze the effects of acute caffeine intake on muscular strength, power, and endurance performance according to CYP1A2 polymorphism in men and women.

Who can participate

Age range

18 Years – 35 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between ≥ 18 and ≤ 35 years. * Body mass index (BMI) lower than 25 kg/m². * Physically active subjects (≥150 min/week of moderate exercise). * Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise. * Participants capable of performing the tests. Exclusion Criteria: * History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism. * Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study. * Body mass index (BMI) ≥ 25 kg/m². * Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. * Performing strenuous exercise within 48 hours prior to the tests. * Failing to replicate the same food intake on the two experimental days. * Consuming caffeine after 6 PM on the day prior to training or testing.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

cyp1a2 polymorphism

Timeframe: Before the beginning of the trial

Mean velocity at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Peak velocity at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Mean power output at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Peak power output and time to reach peak power output at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Number of repetitions performed in 1 set at 65%1RM until task failure

Timeframe: Through study completion, an average of 2 weeks

Bar velocity deplacement performed in 1 set at 65%1RM until task failure

Timeframe: Through study completion, an average of 2 weeks

Trial details

NCT IDNCT06610110

SponsorAlberto Pérez-López

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-30

View on ClinicalTrials.gov More CYP1A2 Polymorphism trials

Plain-language summary

Who can participate

Age range

18 Years – 35 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

cyp1a2 polymorphism

Timeframe: Before the beginning of the trial

Mean velocity at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Peak velocity at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Mean power output at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Peak power output and time to reach peak power output at different %1RM

Timeframe: Through study completion, an average of 2 weeks

Number of repetitions performed in 1 set at 65%1RM until task failure

Timeframe: Through study completion, an average of 2 weeks

Bar velocity deplacement performed in 1 set at 65%1RM until task failure

Timeframe: Through study completion, an average of 2 weeks